gpi-0100
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2000 (NCT00016146)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650396 ↗
Also known as
- gpi0100
- gpi-0100
- gpi-0100
- gpi-0100
- gpi-0100
- tvgv-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02576561 | Phase 2 | Nov 1, 2015 | Clinical Research Management, Inc., THEVAX Genetics Vaccine |
| NCT00485563 | Phase 2 | Jun 1, 2007 | Endocyte |
| NCT00329368 | Phase 1 | Sep 1, 2005 | Endocyte |
| NCT00016146 | Phase 1 | Jul 1, 2000 | Cornell University, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Endocyte | For profit | 2 | 2 | 2 | 2005 |
| Clinical Research Management, Inc. | For profit | 1 | 0 | 1 | 2015 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
| THEVAX Genetics Vaccine | For profit | 1 | 1 | 1 | 2015 |
5 organizations
Page 1 / 1